Pharmaceuticals

Axsome Therap

Axsome Therapeutics Receives FDA Approval for AUVELITY

Mizuho Raises Axsome Therapeutics Price Target to $310

Oppenheimer Increases Holdings in Axsome Therapeutics

Axsome Therapeutics COO sells 4,750 shares after exercising stock options

Mizuho Securities Maintains Buy Rating on Axsome Therapeutics

Needham Raises Axsome Therapeutics Target Price to $267

FactSet lowers Axsome Therapeutics' 2026 EPS forecast

Axsome Therapeutics Reports Strong Q1 2026 Earnings, Core Product Receives FDA Approval for New Indication

Axsome Therapeutics Reports Strong Q1 Earnings, Ovelity Receives FDA Approval

Axsome Therap released FY2026 Q1 earnings on May 4 Pre-Market (EST), actual revenue USD 191.2 M (forecast USD 190.69 M), actual EPS USD -1.2606 (forecast USD -0.8987)

Axsome Therapeutics Reports Q1 Financials

FDA Approves Axsome Therapeutics' AXS-05 for Agitation in Alzheimer's Patients

Axsome Therapeutics AUVELITY® Approved by FDA for Agitation Associated with Alzheimer's

Axsome Therap to Release FY2026 Q1 Earnings on May 4 Pre-Market EST, Forecast Revenue USD 192.46 M, EPS USD -0.8594

Axsome Therapeutics Faces Shareholder Investigation and FDA Decision

Axsome Therapeutics Discusses Product Auvelity Progress at Healthcare Conference

Axsome Therapeutics Launches Solriamfetol Clinical Trial for Depression

Axsome Therapeutics Publishes 2025 10-K Financial Report

Axsome Therap released FY2025 Q4 earnings on February 23 Pre-Market (EST), actual revenue USD 196M (forecast USD 193.26M), actual EPS USD -0.564 (forecast USD -0.6906)

Axsome Therap released FY2025 annual earnings on February 23 Pre-Market (EST), actual revenue USD 638.5 M (forecast USD 635.84 M), actual EPS USD -3.682 (forecast USD -3.7838)

OPTIMI HEALTH CORP

HCW Biologics

GCL Global

Silexion Therapeutics

Micware

Vida Global

MetaVia

MicroAlgo

BiomX

Tradr 2X Long XNDU Daily ETF

Axsome Therapeutics, Inc. (AXSM.US) Q4 2025 Earnings Conference Call

Axsome Therapeutics, Inc. (AXSM.US) Q1 2025 Earnings Conference Call

Axsome Therapeutics, Inc. (AXSM.US) Q4 2024 Earnings Conference Call

AXSM

Axsome Therapeutics is set to launch AUVELITY for Alzheimer’s disease agitation in June, while also expanding its efforts in major depressive disorder (MDD). The company has increased its sales force to 630 representatives and reports 86% payer access for AUVELITY in MDD. The drug's unique mechanism targets NMDA and sigma-1, differentiating it from existing treatments. Axsome anticipates that 80% of prescriptions will be covered under Medicare Part D, with a focus on long-term care facilities. The company aims to leverage synergies between Alzheimer’s agitation and MDD treatments.

Market Beat

Axsome Therapeutics Bets on AUVELITY Expansion With June Alzheimer’s Agitation Launch

Axsome Therapeutics has received FDA approval for AUVELITY, the first treatment for agitation associated with Alzheimer's disease, creating a new commercial opportunity. The stock is currently priced at $216.47, with a 21.5% increase over the past month. Analysts suggest the stock is trading below its fair value, indicating potential upside. Investors should monitor prescription uptake and analyst price targets, while being aware of future safety communications regarding AUVELITY. This approval may enhance Axsome's position in neuropsychiatric treatments and influence revenue expectations in central nervous system disorders.

Simplywall

Axsome’s AUVELITY Alzheimer’s Approval Sparks Valuation And Growth Questions

Mizuho Securities analyst Graig Suvannavejh has maintained a Buy rating on Axsome Therapeutics (AXSM) stock, raising the price target to $310. This revision is driven by an optimistic outlook for Auvelity, with projected peak sales of $5 billion, particularly in major depressive disorder and Alzheimer’s agitation. Despite some skepticism, Suvannavejh believes consensus estimates undervalue Auvelity's potential. Needham also reiterated a Buy rating with a $267 price target on the stock.

Tip Ranks

Truist Financial

Mizuho Financial

Mizuho Financial Group, Inc.

Truist’s Suvannavejh Lifts Auvelity Outlook and Sets $310 Price Target on Axsome Therapeutics Buy Rating

RXRX

LABU

Three companies are set to disrupt the healthcare market by 2030: Tempus AI, Recursion Pharmaceuticals, and Axsome Therapeutics. Tempus AI focuses on precision medicine by aggregating clinical and genomic data to enhance treatment decisions, projecting significant revenue growth. Recursion Pharmaceuticals aims to revolutionize drug discovery through automation and machine learning, though it is still in the investment phase. Axsome Therapeutics targets central nervous system disorders with its fast-acting antidepressant, Auvelity, and is expanding its market reach, showing promising revenue growth despite high operating costs.

nasdaq

Recursion Pharmaceuticals

Tempus AI

Direxion S&P Biotech Bull 3X

Invesco Biotechnology & Genome ETF

Health Care Select Sector SPDR

iShares Global Healthcare

iShares Genomics Immunology and Healthcare ETF

VG Health

iShares US Healthcare Providers

VanEck Biotech ETF

SPDR S&P Biotech

Ark Genomic Revolution ETF

iShares US Pharma

Tradr 2X Long TEM Daily ETF

ALPS Medical Breakthrough

iShares Biotechnology ETF

First Trust NYSE Arca Biotech Index Fd

NVIDIA

Intel

Bayer AG

Bayer

ROCHE HOLDINGS AG

Roche

UBS Group AG

NVIDIA Corporation

Bayer Aktiengesellschaft

3 Stocks Poised to Disrupt the Healthcare Market by 2030

Oppenheimer & Co. Inc. has acquired a new position in Axsome Therapeutics, purchasing 7,076 shares valued at approximately $1.29 million in the fourth quarter. Other investors, including M&T Bank Corp and UBS Group AG, have also increased their stakes in the company. Despite strong revenue growth, Axsome faces challenges such as a profitability miss and insider selling, which may affect investor sentiment. Analysts remain optimistic, with several raising price targets and maintaining positive ratings on the stock, which has a consensus rating of "Moderate Buy."

Oppenheimer

M&T Bank

Wells Fargo

Bank of America

Jefferies Financial

M & T BANK CORP DEP SHS REPSTG 1/400TH INT PERP SER K

M & T BANK CORP PERP NON CUM PFD FIXED FLTG RATE SER H

M & T BANK CORP DEP SHS EA REP 1/400TH SHS SERIES J

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A DD

WELLS FARGO & COMPANY 7.5% PERP CONV PRF CLS 'A' SERIES 'L'

WELLS FARGO & COMPANY DEP SHS REP 1/1000 INT PER PFD SER Y A

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A CC

WELLS FARGO & COMPANY 4.75% DEP SHS 1/1000 NCUM PFD CL A SR Z

WELLS FARGO & COMPANY DEP SHS REP 1/1000TH INT PFD SR AA (CLA)

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

Oppenheimer & Co. Inc. Takes $1.29 Million Position in Axsome Therapeutics, Inc. $AXSM

Axsome Therapeutics COO Mark Jacobson sold 233 shares of stock at an average price of $228.18, totaling $53,165.94. Post-sale, he holds 4,517 shares valued at $1,030,689.06, marking a 4.91% decrease in ownership. The transaction was disclosed to the SEC. The company's stock traded down 0.3% to $223.06, with a market cap of $11.47 billion. Axsome reported a quarterly loss of $1.26 EPS, missing estimates, but revenue increased 57.4% year-over-year to $191.20 million. Analysts maintain a consensus rating of "Moderate Buy" with an average price target of $251.89.

ROYAL BANK OF CANADA

Morgan Stanley

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

Insider Selling: Axsome Therapeutics (NASDAQ:AXSM) COO Sells 233 Shares of Stock

Axsome Therapeutics has raised its peak sales projection for Auvelity to $8 billion following FDA approval for treating Alzheimer’s disease agitation. This is a significant increase from the previous estimate of $2.5 billion to $6 billion. The company anticipates a 50-50 revenue split between its two indications. Following the approval, Axsome's share price rose by 23%. Analysts have adjusted their revenue forecasts, with Mizuho Securities increasing its estimate to $5 billion. Auvelity's sales reached $153 million in Q1, up 59% year-over-year, and the company plans to expand its sales force to support the launch in the ADA indication next month.

Fiercepharma

Otsuka Holdings Co., Ltd.

Otsuka Pharmaceutical

Axsome increases Auvelity's peak sales projection to $8B

NVCR

Three overlooked biotech stocks, Axsome Therapeutics, NovoCure Limited, and MBX Biosciences, are poised for growth by 2026. Axsome recently received FDA approval for Auvelity, targeting agitation in Alzheimer's patients, while NovoCure's Tumor Treating Fields technology gained approval for advanced pancreatic cancer treatment. MBX is developing innovative obesity therapies and has sufficient funding to support its operations until 2029. Despite current unprofitability, these companies are expected to capitalize on their recent advancements and market opportunities.

MBX Biosciences

Novocure

Eli Lilly

Novo Nordisk AS

3 Overlooked Stocks Set to Soar in 2026

Mizuho Securities analyst Graig Suvannavejh has maintained a Buy rating on Axsome Therapeutics (AXSM) with a price target of $310.00. Suvannavejh, who focuses on the Healthcare sector, has an average return of 19.9% and a success rate of 48.98% on his stock recommendations. Additionally, H.C. Wainwright's Ram Selvaraju also issued a Buy rating for Axsome Therapeutics, while Morgan Stanley maintained a Hold rating on the stock.

Insmed

Verastem

Immuneering

Mizuho Securities Keeps Their Buy Rating on Axsome Therapeutics (AXSM)

Jason Gerberry from Bank of America Securities reiterated a Buy rating on Axsome Therapeutics, raising the price target to $276. He cites Auvelity’s expanding commercial opportunity in Alzheimer’s disease agitation and management’s $8 billion peak sales ambition as key factors. The upcoming launch and a strengthened sales force are expected to drive growth. Needham also assigned a Buy rating with a $267 target. Gerberry is a 5-star analyst with an 18.9% average return and a 61.32% success rate.

- In a report released yesterday, Jason Gerberry of Bank of America Securities reiterated a 'Buy' rating on Axsome Therapeutics with a target price of $276.00.  
- His rating is based on various factors related to Auvelity's expansion opportunities, projecting peak sales of $8 billion, which he believes is not fully reflected in the current stock price.  
- The report highlights key growth drivers, including a strong pipeline in major depressive disorder and the upcoming Alzheimer's agitation treatment.

Ionis Pharma

Alkermes

BioMarin Pharma

Buy Rating Reiterated as Auvelity’s Expanded Alzheimer’s Opportunity Drives Upgraded $276 Price Target

Axsome Therap(AXSM.US)